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Abstract
Nitric oxide (NO), a crucial signaling molecule, is synthesized by the nitric oxide syn-
thase (NOS) enzyme. The significant effects of NOS are under exploration, and the roles 
of potential therapy targets for diseases of NOS are widely accepted. In this chapter, we 
summarized the important roles of NOS mainly on pathogenesis of prostate diseases, 
male infertility, erectile dysfunction and, addition, the potential therapeutic efficacies of 
NOS for those diseases.
Keywords: nitric oxide synthase, nitric oxide, prostate cancer, male infertility, erectile 
dysfunction, male reproduction
1. Introduction
Urology and andrology are the branches of medicine that focus on urinary tract system and 
male reproductive organs. In recent years, incidences of diseases in urology and andrology 
system such as prostate cancer and male infertility are increasing and causing heavy burden 
to our society. Growing studies have been demonstrating that nitric oxide synthase (NOS), 
which synthesized nitric oxide (NO) by converting L-arginine to L-citrulline, locates in tissues 
of urinary and male reproductive system and acts as key regulators for sexual function, male 
reproduction, cancer progression and so on [1–3]. The aims of this chapter are to present the 
roles of NOS and the recent advances of regulation and therapy function with regard to sexual 
function, male infertility, prostate carcinoma, Peyronie disease, priapism and cryptorchidism.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. NOS and male sexual function
2.1. NOS and erectile dysfunction
Erectile dysfunction (ED) refers to the symptom that the penis cannot reach and (or) maintain 
the adequate erection to complete the satisfaction of sexual intercourse, and the course of dis-
ease will last at least 6 months or more. Penile erection is an integrated process of artery blood 
supply and cavernous blood storage launched by nerve, and during this process, neurotrans-
mitter plays an important role [4]. NO is a main messenger, which involves in the induction 
and maintenance of erection through hemangiectasis and corpus cavernosum relaxation [5]. It 
has been clear that NO penetrates the smooth muscle cell membrane and catalyzes the forma-
tion of cGMP after combining with the ornithine enzyme on the iron ring and then changing 
the intracellular calcium concentration of smooth muscle to cause relaxation.
2.1.1. NOS in penile tissue
The nNOS and iNOS were found in the central nervous system, especially the hypothalamic 
area, such as paraventricular nucleus and the medial optic zone, that control the erectile 
and sexual behavior and also regulate penile erection through spinal nerve centers [6, 7] 
(Figure 1). Specially, nNOS mainly distributes in the penile and pelvic nerve plexus in adult 
rats, whereas eNOS is in the penis and pelvic area of the urethra but less in the body part 
of the penis [8, 9].
Figure 1. Role of NOS and NO in penile erection. The nNOS and iNOS regulate penile erection through NO/cGMP/
PKG pathway. Abbreviations: eNOS, endothelial nitric oxide synthase; nNOS, neuronal nitric oxide synthase; NO, nitric 
oxide; GTP, guanosine triphosphate; cGMP, cyclic guanosine monophosphate; PKG, protein kinase G.
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2.1.2. Current reviews on the effects of NOS on disease-related ED
2.1.2.1. Diabetes-related ED
A possible percentage ranges from 50% to 90% of diabetes patients suffer from ED [10], which 
counts around three times more than that in healthy cohort. Also, previous report showed 
that diabetes patients who firstly suffered from ED had a younger age in average compared 
with people without diabetes and more severe appeared of their symptoms [11]. It has now 
reached a consensus on the relationship between diabetes and ED, the damage of endothelial 
cell, ultrastructure changes in cavernous smooth muscle and matrix fibrosis are the common 
factors affecting the cavernous diastolic function and resulting in ED [12], and damage of 
eNOS-NO-cGMP pathway was considered to be the main molecular mechanism [13]. The 
expression of Recombinant Nitric Oxide Synthase Trafficker (NOSTRIN) in Dulbecco’s modi-
fied eagle medium (DMED) corpus cavernosum increased while the expression of eNOS 
decreased. It is theorized that increased NOSTRIN may be an important mechanism for the 
reduction of eNOS expression, while further study is still needed [14].
2.1.2.2. Benign prostatic hyperplasia-related ED
Approximately 49% of BPH patients suffer from ED. A significant correlation was reported bet-
ween BPH/lower urinary tract obstruction (LUTS) and ED after excluding the effects of age and 
other etiologies on ED [15, 16]. BPH/LUTS seems to be one of the most harmful factors contribute 
to ED compared with diabetes, hypertension and (or) heart disease [17]. In fact, both parasym-
pathetic innervation of prostate and cavernous nerve of penis are from the pelvic plexus [18]. 
Pathophysiology studies also showed that the mechanisms of BPH are similar to those of sexual 
dysfunction which include decrease of the ratio of endothelial NOS/NO, enhancement of endo-
thelial presenilin-1 contraction effect, overreaction of autonomic nervous of bladder, prostate 
and penis, enhancement of signaling pathway Rho kinase expression/activity and (or) pelvic 
vascular sclerosis [19]. Since NOS has been found to play significant effects on BPH patients with 
ED, new treatment by exogenous NO donor and NOS activating enzyme would be promising 
[20]. However, only few animal experiments have been under exploration up to date, and the 
mechanisms for the occurrence of ED in BPH patients are still needed to be identified.
2.1.2.3. Hypertension-related ED
Hypertension is another important risk factor for ED. Jensen et al. reported that nearly 27% of 
hypertensive patients suffered from ED [21]. The increase of plasma asymmetrical dimethylar-
ginine (ADMA) concentration caused reduction of the NO expression in penile tissue by inhib-
iting the NOS activity, which might be a possible mechanism for hypertension-related ED [22].
2.1.3. Possible therapy strategies of NOS on ED
Increasing evidence has been indicating that L-Arg-NO-cGMP pathway might be a crucial 
mechanism of penile erection [23]. As a key enzyme in the synthesis of NO, NOS has always 
been one of the research focuses. Specially, nNOS acts as a key role in erection launch, whereas 
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eNOS enables cavernous body dilate and maintains the status of erection [24]. Although the 
effect of iNOS was absent in the direct regulation of penile erection, a special “double effect” 
in the elderly and the pathological state was reported [25]. Since the reduction of NOSs or 
the decrease of its activity might contribute to ED, the treatment on L-Arg-NO-cGMP for ED 
might be revolutionary breakthrough, as phosphodiesterase type 5 inhibitors (PDE5Is) was 
found to improve the erectile function by increasing the NO concentration but reducing the 
eGMP degradation [26]. However, nearly 20% of patients with ED still showed little benefit 
after receiving PDE5Iss, especially in patients with diabetes or prostate cancer (Prostate carci-
noma) after radical mastectomy [27]. Future NOSs gene transfer therapy from the molecular 
level would be another choice [28], which might have long-term curative effect, little side 
effect to the body and, even, completely cure ED. Therapies including increasing expression 
of NOSs (nNOS, iNOS, eNOS) or inhibiting the expression of protein inhibitor of NOS (PIN) 
might be promising and worthwhile exploration [29]. However, shortcomings such as short 
effect duration, possibility of inducing abnormal erection and other potential unknown side 
effects from the long-term excessive expression of NO are addressed.
2.2. NOS and libido
ED may cause low sexual desire or loss of libido in men [30]. Previous study reported that 
treatment for ED could somehow retrieve sexual desire [31]. It is believed that NO and NOS 
are beneficial for penile erection, and consequently, NO and NOS may enhance sexual moti-
vation in indirect ways. NO could also affect libido in the direct ways.
Areas for male sexual behavior in brain distribute NO responsive guanylyl cyclase, which 
involves cellular events of NO [32], and previous studies showed that the NOS inhibitor 
 NG-nitro-L-arginine methyl ester (NAME) administered to medial preoptic area by reverse 
dialysis caused reduced mounting of male rat [32, 33]. Chu et al. further reported that Impaza, 
a stimulator of eNOS, could raise the sexual incentive motivation rates of male rats through the 
NO-guanylyl cyclase pathway [34], and nNOS was also considered to affect the male sexual 
behavior by activating the cyclic guanosine monophosphate (cGMP) [35]. However, adverse 
result was reported by other researchers, and the conclusion was still controversial [36].
3. NOS and male infertility
Approximately 15% of couples suffer from infertility while male cause contributed to nearly 50% 
in these infertile couples [37]. Male reproduction is known to involve complicated aspects such 
as spermatogenesis, sperm dynamics, sperm morphology and acrosome reaction. Increasing 
evidences have been indicating that NOS and NO are associated with male infertility [38].
3.1. NOS and male reproductive system
The hypothalamic-pituitary axis plays core roles in reproduction and steroid hormone pro-
duction in man. Gonadotropin-releasing hormone (GnRH), also known as luteinizing hor-
mone-releasing hormone (LHRH), which is produced and secreted by the arcuate nucleus 
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of the hypothalamus, could stimulate the anterior pituitary to episodically release follicle-
stimulating hormone (FSH) and luteinizing hormone (LH). LH stimulates the Leydig cells to 
produce testosterone, and FSH exerts its effect directly on the Sertoli cells to promote sper-
matogenesis (Figure 2).
In vitro studies have shown that NO stimulates LHRH secretion from the hypothalamus and 
modulates LH release from the pituitary [39, 40]. Ceccatelli [41] reported that sodium nitro-
prusside, a NO donor, suppressed GnRH-stimulated LH release from pituitaries in male rats. 
Chatterjee et al. [42] showed that NOS inhibitor p-nitro-L-arginine methyl ester (L-NAME) 
enhanced GnRH-induced LH release from pituitaries in rats. Decreased level of GnRH and 
gonadotropin in chronic NO deficiency rats were also observed [43].
3.1.1. Testis
3.1.1.1. Testicular microcirculation
The testis has a rich vascular system that plays a very important role in maintaining the nor-
mal functions and stable inner environment of the testis [44]. The regulation of testicular 
blood microcirculation is very complex, including self-regulation, neural regulation and 
humoral regulation [45]. NO is the major physiological regulator of basal blood vessel tone 
and is continually released from endothelium of testicular arteries [46]. A study showed that 
the regulation effect of NO on testicular blood flow was limited under basal conditions, but 
this limitation could be significant reversed after HCG treatment; in this case, NO showed 
Figure 2. Regulation of hypothalamic-pituitary axis. Abbreviations: LHRH, luteinizing hormone-releasing hormone; 
GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; FSH, follicle-stimulating hormone.
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the effects of increasing blood flow and inhibiting leukocyte accumulation on rat testicular 
arteries [46]. NO is also an important factor in regulating testicular vessel tension at different 
temperatures, at 34–37°C, disturbance of testicular arteries reaction appeared after L-NAME 
treatment [47]. Interestingly, NO content and NOS activity could be significantly increased at 
abnormal high temperatures caused by varicose spermatic veins in varicocele patients [48].
3.1.1.2. Leydig cells
Leydig cells, also known as interstitial cells, are adjacent to the seminiferous tubules in the 
testicle. Leydig cells produce and release testosterone under the control of LH and act as auto-
crine and/or paracrine hormones in gonad under the modulation of NO [49]. An immunohis-
tochemistry study demonstrated that eNOS, nNOS and iNOS all expressed in  cytoplasm of 
Leydig cells in rat testis [50]. Interestingly, a testis-specific subclass of nNOS, known as the 
truncated form of nNOS (TnNOS), has been recently identified as a major contributor to the 
formation of NO [51]. TnNOS has been found to be localized solely in the Leydig cells of the 
testes but neither in the Sertoli nor germ cells [51], which enable us to predict that NO may 
associate with functions of Leydig cells. Kozieł et al. found that NOS was able to act directly 
within the male gonad by means of regulating androgen secretion though Leydig cells [52]. 
Another study showed that stress-induced stimulation of the testicular NO signaling path-
way leaded to the inhibition of steroidogenic enzymes [53]. But NOS seemingly exerted a 
biphasic effect on testosterone secretion [54]. At low concentrations, NO exerted a transient 
stimulatory effect on testosterone secretions mediated by cyclic GMP, whereas at high con-
centrations, it inhibited steroidogenesis by Leydig cells.
3.1.1.3. Sertoli cells
Spermatogenesis is a complex process in which Sertoli cells closely involve, and NOS also 
plays a crucial role in this process through Sertoli cells. Zini et al. [55] showed that eNOS 
protein located in Sertoli cells and some parts of germ cells in seminiferous tubules, especially 
in degenerating germ cells and spermatids in histologically normal testes. The iNOS was also 
found in Sertoli cells, as well as a small subset of pachytene spermatocytes and elongated sper-
matids in the normal testis [56]. However, iNOS expression could be very intense in Sertoli 
cells in pathological conditions, for example, the absence of seminiferous tubules [57]. iNOS 
involves in germ cell death in testicular ischemia-reperfusion injury model, and inhibition of 
iNOS could improve impaired spermatogenesis [58]. In cryptorchidism model, the transgene 
expression of eNOS increased testicular germ cell apoptosis. In iNOS⁄mice, the numbers of 
spermatocytes, spermatids and Sertoli cells per tubule were significantly more than those 
with wild-type testes [59]. A possible conclusion could be drawn that NO plays an important 
role in both numerical and functional regulation of key somatic cells in the testis, which in 
turn impacts on germ cells and their survivals during the process of daily sperm production.
3.1.1.4. Epididymis
The main functions of the epididymis are promoting spermatozoa mature and storing sper-
matozoa [60]. An immunostaining study in human epididymis showed that NOS almost 
exclusively located in the epithelium [55], and the greatest concentration was in the adluminal 
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region [55]. It suggests that NOS may involve secretion and/or absorption of epididymal fluids, 
or in another way diffuse into the tubule lumen to affect nearby spermatozoa. Another study 
showed a similar distribution of NOS protein in rat epididymis, speculating that epididymal 
NOS protein might contribute to spermatozoa maturation [61].
3.2. NOS and sperm function
Approximately 15% of couples suffer from infertility while male cause contributed to nearly 
50% in these infertile couples [37]. Male reproduction is known to involve complicated 
aspects, such as spermatogenesis, sperm dynamics, sperm morphology and acrosome reac-
tion. Increasing evidences have been indicating that NOS and NO are associated with male 
infertility [38].
3.2.1. Sperm motility, morphology and viability
Sperm motility is an essential factor for male fertility. Low sperm motility, also referred as 
asthenozoospermia, is one of the major causes to male infertility [62]. Previous study indicated 
that nearly 80% of semen samples from infertile males were defective in sperm motility [63]. 
Hellstrom et al. reported for the first time that sodium nitroprusside, a NO releaser, was bene-
ficial for maintenance of thaw-sperm motility by reducing lipid peroxidative damage to sperm 
membranes. Significantly improved motion parameters of sperm were observed in semen 
samples treated with sodium nitroprusside in concentrations of 50 and 100 nM compared to 
control samples, and this beneficial effect maintained for 5–6 hours after thaw [64]. However, 
NO concentration in normozoospermic fertile men was observed to be significantly lower than 
those of asthenospermia infertile men [65]. In fact, the effect of NO seems to be double-sided, 
low concentration of NO improves sperm motility, while high concentration contributes to 
adverse effect [66]. Herrero et al. reported that a significant decrease on sperm motility was 
observed in semen samples treated with sodium nitroprusside in a higher concentration of 
300 mM, and this effect could be blocked by hemoglobin, a scavenger of NO, as sperm motil-
ity in samples furtherly treated with hemoglobin was significantly higher than those without. 
While when the incubating concentration of sodium nitroprusside reduced to 150 mM, no 
modifications of sperm motility were found [67]. Besides, the other NO releaser, S-nitroso-
N-acetylpenicillamine (0.012–0.6 mM), along with sodium nitroprusside (0.25–2.5 mM), was 
found to decrease percentage of forward progressive sperm motility and straight line velocity 
in a concentration-dependent manner [68].
As to sperm morphology and viability, the effects of NO reveal controversial contributions. a 
positive correlation between NO with defects in sperm morphology has been found in male 
with normal sperm rate ≥14% but a negative correlation with defects in sperm morphology 
in male with normal sperm rate <14% [69]. However, later study failed to find any signifi-
cant association between NO production and sperm morphology [70]. Researchers reported 
that semen treated with 0.25–2.5 mM sodium nitroprusside revealed significantly less sperm 
bound to the zona pellucida compared with the control group which treated without NO [71], 
whereas some other researchers reported no any significant effect of NO on sperm viability 
[66, 69, 72]. And meanwhile, low concentration of NO also plays a role in the maintenance of 
sperm viability after cryopreservation and post-thaw sperm [65, 66, 68].
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3.2.2. Capacitation, hyperactivation and acrosome reaction
Capacitation is a process in which spermatozoa acquire the ability to bind to the egg’s zone 
pellucida and fertilize an oocyte during their transit in the female genital tract [73, 74]. 
Capacitation involves in some molecular events, and it was clear that low level of NO from 
NO-releasing agents induces human sperm capacitation [75]. Indeed, it has been reported 
that NO-releasing compounds significantly benefit the capacitation, whereas NO inhibi-
tors decrease this process [76]. In fact, NO produced by spermatozoa involves in a cascade 
of molecular events of capacitation, which is needed over the course of this process [77–79].
Hyperactivation can be treated as a subcategory of capacitation. Hyperactivation of sperma-
tozoa exhibits high amplitude and asymmetric flagellar movement, non-linear motility and 
penetrate the oocyte with strong propulsive force [70, 80]. The effect of NO on hyperactiva-
tion was found to be similar to which on sperm motility, little concentrations of NO increased 
spermatozoa hyperactivation, whereas excessive concentrations decreased the hyperacti-
vated spermatozoa motility [81, 82].
Acrosome reaction denotes the process that capacitated and hyperactivated motility sperm binds 
to the zona pellucida and continues to pass through the exocytotic release of proteolytic enzymes 
from the acrosome so that to bind to the mature ovum. The amount of NO influenced the acro-
some reaction, and increased amount of sperm was observed to undergo the acrosome reaction 
with the presence of NO donor compound [83]. Meanwhile, significantly increased amount of 
sperm was found to bind to membrane of the ovum with their plasma membrane [84].
3.2.3. Sperm mitochondria
Mitochondria in sperm activate as a generator which supply sperm with energy for the pro-
cess of motility, acrosome reaction, oocyte fusion, fertilization and so on [85]. NO has been 
reported to involve in functions of mitochondrial that include biogenesis, remodeling and 
mitochondrial respiration [86–88]. Specially, different levels of NO could cause different 
sperm mitochondrial functions, low concentrations of NO enhanced the sperm motility, while 
NO with higher levels cause mitochondrial hyperpolarization and sperm apoptosis [64, 89]. 
This might explain the adverse effects of various concentrations NO on sperm motility.
3.3. Single-nucleotide polymorphisms of NOS and male infertility
Genetic variations are crucial etiological factors contribute to male infertility. Up to date, some 
single-nucleotide polymorphisms (SNPs) have been identified to involve in sperm defects 
and male infertility in ethnic populations. Polymorphisms T786C and G894T of eNOS were 
reported to decrease sperm motility and quantity by increasing the seminal oxidative stress 
in Egyptian infertile male population [90]. Similar results of G894T were reported in Italian 
and Iranian infertile male populations [91, 92], and this SNP also found to be associated with 
higher level of sperm DNA fragmentation in Chinese infertile males [93]. The polymorphism 
4a4b, which refers to a sequence variant with variable sequence of tandem 4a4b repeats in 
intron 4, was found to be associated with poor sperm morphology and male infertility in a 
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Korean and Chinese population [94, 95]. Associations between SNPs of NOS and male infer-
tility are under exploration, which would be promising tools for diagnosis or further curing 
male infertility.
3.4. Possible therapy strategies of NOS on male infertility
Increasing evidences has been showing that inappropriate concentration level of NO may 
contribute to male infertility in some extend by means of decreasing sperm motility and nor-
mal sperm morphology, reducing efficiency of capacitation and acrosome action. It is reason-
able to consider possible therapy strategies to the utilization of NOS donors or inhibitors so 
that to adjust the concentration of NO to the “right” level. In fact, significantly higher fertile 
rate was observed in animal experiment in vitro, and further researches would be needed to 
warrant the potential benefits for human beings.
4. NOS and prostate carcinoma
Prostate carcinoma is one of the most common cancers among men and second in cancer-
related deaths in the United States. An estimated study predicted that there will be 180, 890 
new prostate carcinoma cases and 26, 120 deaths due to the disease in the country in 2016 [96]. 
Etiological studies implicated that multiple reasons involved in prostate carcinoma suscepti-
bility, such as dietary, environment, hormone status and genetic factors [97]. Growing stud-
ies indicated that NOS and NO system play crucial roles in progression of human prostate 
carcinoma [98–100].
The physiological functions of NO are dependent primarily on concentrations. Low concen-
tration of NO acted as a signal transducer and affects many physiological processes including 
blood flow regulation, platelet activity, iron homeostasis, cell proliferation and neurotrans-
mission, whereas, in high concentrations, it exerted a cytotoxic protective effect, for example, 
to against pathogens and perhaps tumors [101, 102].
4.1. Role of nitric oxide synthase in cancer biology
The roles of NOS and NO on DNA damage, apoptosis, cell cycle, enhancement of cell pro-
liferation, angiogenesis and metastasis are currently viewed, and NO was found to be asso-
ciated with tumor environment, for example, the vasculature cells and other stromal cells 
[103–105]. Research also indicated that NOS2 expression was correlated with tumor vascular-
ization, accumulations of p53 mutations and activation of epidermal growth factor receptor, 
even could be treated as an independent predictor of poor survival in women with estrogen 
receptor (ER)-negative breast tumors [106]. Low concentrations of NO acted as a promotional 
role in angiogenesis which stimulates tumor progression by providing blood flow access to 
the tumor and subsequently resulting in cell proliferation. On the contrary, high levels of NO 
tend to be cytotoxic to cancer cells [107]. While in animal models, iNOS overexpression pro-
duced either pro-tumor or anti-tumor effect on tumor growth, these alterable effects seem to 
be dependent on the tumor microenvironment and the tumor type itself [104, 108]. The effects 
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of NO possibly differ in expression level of iNOS, duration and timing of NO delivery, the 
microenvironment, the genetic background and the cell type (Figure 3) [109].
4.2. NOS and proliferation of prostate carcinoma
NO generated by eNOS or iNOS might be involved in prostate proliferation. At low concentra-
tions, NO acted as a signaling molecule regulating smooth muscle relaxation and blood flow, 
neurotransmission, platelet activity, iron homeostasis, cell survival and proliferation, while at 
high concentrations acted as modulating immune-mediated anti-tumor activities [110, 111]. 
Concentration of NO less than 100nM had an effect of preventing certain cell types from apop-
tosis and thereby favors tumorigenesis and progression [112]. Higher expression of iNOS 
was detected in cancer specimens than that in normal tissues of prostate carcinoma patient. 
Aaltoma et al. also demonstrated a positive association between expression level of iNOS and 
rapid cancer cell proliferation rate, dedifferentiation and advanced stage cancer [113]. A recent 
study has shown that NO also regulated cell proliferation in a pathway of CPD-Arg-NO [114].
4.3. Nitric oxide synthase and angiogenesis of prostate carcinoma
Angiogenesis is a critical molecular event in tumor progression [115, 116]. Epidermal growth 
factor receptor (EGFR) signaling pathway, tumor suppressor p53 and VEGF, which are collec-
tive mediators that exacerbate angiogenesis can be stimulated by NO [115, 117]. The involve-
ment of eNOS in the NO-induced human endothelial and prostate carcinoma cell migration 
was further warranted [116]. Recent research also reported that NO played vital roles in 
maintaining blood supply for prostate carcinoma, and an anti-tumor vascular activity effect 
revealed with presence in inhibition of NOS [115].
4.4. Single-nucleotide polymorphisms of NOS and susceptibility of prostate carcinoma
Several studies suggested that polymorphisms of some NOS genes were genetic  susceptibility 
 factors for prostate carcinoma, especially for aggressive diseases [118, 119]. A plethora of meta-
analyses has identified eNOS gene polymorphisms as strong susceptibility factors for the 
progression toward prostate carcinoma [120]. Another study also reported that NOS3 gene 
Figure 3. Roles of NO in prostate cancer. Abbreviation: NO, nitric oxide.
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 polymorphisms were genetic susceptibility factors for the progression of prostate carcinoma and 
poor patient outcomes [121]. A meta-analysis conducted by Zhao et al. suggested that eNOS gene 
894G > T polymorphism contributed to aggravate the onset of prostate carcinoma in males [122]. 
Nikolic et al [123] also corroborated the involvement of eNOS or NOS3 gene in the pathogenesis 
of prostate carcinoma. NOS3 rs1799983 polymorphism augmented the risk of prostate carcinoma 
in various populations. As one of the possible mechanisms, the involvement of NO receptor com-
ponent, sGC-1, in mediating the proliferation of prostate carcinogenesis, has been surmised [124].
4.5. Possible therapy strategies of NOS on prostate carcinoma
Anti-cancer agents such as gold lotion have successfully demonstrated their anti-carcinogenic 
potential through the regulation of both iNOS and eNOS [125–127]. Yu et al. [128] also elucidated 
the significance of eNOS as a seemingly promising strategy for targeting anti-androgen resistant 
prostate carcinoma. Arginine-releasing compounds such as carboxypeptidase-D increased NO 
production, which slackened progression of prostate carcinoma so that prolonged survival time 
[129]. NO-donor drugs also have been under increasing explorations. A few NO-donor drugs 
have been confirmed to have favorable anticancer activity and could be potential anticancer ther-
apies [3, 130]. GIT-27NO, a novel NO donor, inhibited the growth of PC3 and LnCap prostate 
carcinoma cells xenografted into nude mice in a concentration-dependent manner [131]. And 
DETA-NONOate was revealed to inhibit epithelial-mesenchymal transition (EMT) and invasion 
of human prostate metastatic cells by producing large amount of NO [132]. It is sensible that 
novel NOS-based therapeutics may prove valuable in the future treatment of prostate carcinoma.
5. NOS and other urinary and male reproductive diseases
5.1. Peyronie disease
Peyronie disease (PD) is an intractable, sexually dysfunctional disease resulting in penile cur-
vature, penile pain, penile deformity, difficulty with coitus, shortening, hinging, narrowing 
and ED. Mechanisms of PD have not been fully elucidated. A recent hypothesis was that 
the recurrent microtrauma of the tunica albuginea caused small damages that activated pro-
cesses of wound healing and fibrotic plaque development during sexual intercourse [133]. 
Inflammatory cells and iNOS accumulated in the process of wound healing, the increased 
NO then led to the myofibroblasts and proliferation of fibroblasts and redundant collagen 
between the layers of the tunica albuginea (penile plaque) [134]. Although surgical therapy is 
now the first-option for PD patients, researchers are focusing on the nonsurgical treatments 
of PD, and NOs inhibitors might be a promising choice [135].
5.2. Priapism
Priapism is defined as a persistent and painful erection that lasts longer than 4 hours without 
sexual stimulation and can lead to ED [136]. The relation between penile erection and produc-
tion of NOS has been well investigated: nNOS and eNOS were the causes of both the initiation 
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and maintenance phases of penile erection [137]. However, decreased function in NO gener-
ated by decreased activation of eNOS resulted in PDE5 downregulation that was thought to 
be a derivate of NO and, therefore, reduced basal levels of PDE5 and caused priapism [138].
5.3. Cryptorchidism
Cryptorchidism denotes failure of the movement of the testis to the scrotum, and in most cases, 
it raises risk of testicular germ cell cancer and subfertility later in patients’ life course. Testicular 
germ cell apoptosis which causes by exposure of testicular in elevated temperature and oxidative 
stress is the primary etiology of infertility. Animal models with cryptorchidism induced by sur-
gery revealed that eNOS played a significant role in mouse spermatogenesis in cryptorchidism-
induced apoptosis [139]. Contemporaneously, reduced rate of testicular atrophy was observed 
in heterozygous Hoxa 11 knockout mice which had congenital bilateral cryptorchidism when 
early treated with Nomega-nitro-L-arginine methyl ester (L-NAME), a NOS inhibitor [140].
6. Conclusion
It has been becoming evident that redox regulation driven by NOS and NO represents a 
promising tool for exploring fundamental diseases process and new development of strate-
gies to treat urinary, male reproductive and sexual diseases.
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